Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27467| Title: | Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance. | Austin Authors: | Cochrane, T;Campbell, B A;Gangatharan, S A;Latimer, M;Khor, Richard ;Christie, Drh;Gilbertson, M;Ratnasingam, S;Palfreyman, E;Lee, H P;Trotman, J;Hertzberg, M;Dickinson, M | Affiliation: | Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia Sir Peter MacCalllum Department of Oncology, the University of Melbourne, Victoria, Australia Dept of Haematology, Gold Coast University Hospital, QLD Griffiths University, QLD Fiona Stanley Hospital, Perth, WA University of Western Australia, WA Department of Radiation Oncology, Melbourne, Victoria Austin Health Genesiscare, Gold Coast, QLD, Australia Monash Health, Melbourne, Victoria, Australia School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia Dept of Haematology and Oncology, Western Health, Melbourne, Victoria, Australia Andrew Love Cancer Centre, University Hospital Geelong, Melbourne, Victoria, Australia Flinders Medical Centre, Adelaide, South Australia Concord Repatriation General Hospital, Sydney, New South Wales, Australia University of Sydney, Sydney, New South Wales, Australia Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia University of NSW, Sydney, New South Wales, Australia ACT Pathology and Canberra Hospital, ACT Royal Darwin Hospital, Northwest Territories, Canada Bond University, Gold Coast, QLD, Australia |
Issue Date: | 9-Sep-2021 | Date: | 2021-09-09 | Publication information: | Internal Medicine Journal 2021; online first: 9 September | Abstract: | The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management HL. This article is protected by copyright. All rights reserved. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/27467 | DOI: | 10.1111/imj.15503 | ORCID: | 0000-0002-2668-1399 0000-0001-8009-4593 0000-0002-1492-5966 |
Journal: | Internal Medicine Journal | PubMed URL: | 34505342 | Type: | Journal Article | Subjects: | HL Hodgkin Lymphoma PET adapted chemotherapy radiotherapy |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.